Omalizumab (Xolair) inj 150 mg prefilled syringe: Supply issue resolved
There was a delay to a delivery of Xolair inj 150 mg prefilled syringe (Pharmacode: 2555042)
28 August 2024 Update
Stock has arrived and been distributed to wholesalers.
Affected product
There was a delay to a delivery of omalizumab (Xolair) inj 150 mg prefilled syringe.
- Chemical: Omalizumab
- Presentation: Inj 150 mg prefilled syringe
- Brand: Xolair
- Pharmacode: 2555042
- Subsidy: $450.00
- Measure / Qty: per 1
It did not affect the 150 mg vial presentation (Pharmacode 2243369).
Schedule listing for omalizumab(external link)
HML listing for omalizumab(external link)
Alternative product
Novartis, the supplier, supplied an Australian version of this product. It was listed from 29 July 2024.
Product | Batch Number |
Presentation | Novartis Code |
Pharmacode | Pack Size |
Price | Stock Status |
---|---|---|---|---|---|---|---|
XOLAIR (Australian product) |
AVXS28110 | 150 mg pre- filled syringe |
731521 | 2687925 | Per 1 | $450.00 | Available from 18 July |
Medsafe has approved the use of this product in New Zealand. All pharmacological aspects of the two
products are identical. However, the Australian pack includes the Australian prescribing information as an insert.
Please refer to the New Zealand Data Sheet and Consumer Medicines Information for the New Zealand details.
Xolair Datasheet – Medsafe [PDF](external link)
Xolair Consumer Medicines Information – Medsafe [PDF](external link)
Information for Pharmacists
This listing will not appear in the Online Schedule until it is updated for 1 September 2024.
- RxOne users: the changes will be automatically updated by RxOne from the effective date.
- ScriptSense users: the listing will be automatically updated by ScriptSense from the effective date
- TONIQ users: the changes will automatically be updated in Toniq medicine databases from the effective date.
The Sector Operations Group won’t be able to process claims for July dispensing of the above listings. Pharmacies can either:
- hold these claims until August OR
- reclaim them in August when they are rejected for payment in July claims.
Resupplied August 2024
Novartis advised that supply has returned to normal.
Who to contact
If you have questions about this issue, email enquiry@pharmac.govt.nz
Please include as much information as you can about the product (presentation, brand, pharmacode) and who your wholesaler is.
Sign up to our email list for regular emails about supply issues and more(external link)